# EDGAR Filing Document

**Accession Number:** 0001760542
**File Stem:** 0001104659-25-075595
**Filing Date:** 2025-8
**Character Count:** 2686
**Document Hash:** 6c1b5aef28bb5264abf3ed2565c08016
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-075595.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001104659-25-075595

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**EFFECTIVENESS DATE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HOOKIPA Pharma Inc.
- **CENTRAL INDEX KEY:** 0001760542
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 815395687
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38869
- **FILM NUMBER:** 251197246

**BUSINESS ADDRESS:**
- **STREET 1:** 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** 0114318906360

**MAIL ADDRESS:**
- **STREET 1:** 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER**

**SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION**

**OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934.**

**Commission File Number: 001-38869**

**HOOKIPA Pharma Inc.**

(Exact name of registrant as specified in its charter)

**350 Fifth Avenue, 72nd Floor, Suite 7240**

**New York, NY 10118**

**+43 1 890 63 60**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common Stock, par value $0.0001 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | x |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ¨ |
| Rule 15d-22(b) | ¨ |

---

Approximate number of holders of record as of the certification or notice date: 56

Pursuant to the requirements of the Securities Exchange Act of 1934, HOOKIPA Pharma Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: August 8, 2025 | By: | /s/ Malte Peters |
|  | Name: | Malte Peters |
|  | Title: | Chief Executive Officer |

---